Labcorp to Provide Invitae Tests in NCI Trial to Boost CRC Germline Screening
LH•Labcorp will provide Invitae genetic tests for a trial employing outreach to boost germline testing in colorectal cancer families, where inherited variants cause 10% of cases but under one third of at-risk relatives are tested. It will also measure how multigene panel testing affects care for newly diagnosed patients.
1. Collaboration Details
Labcorp is collaborating with the Alliance for Clinical Trials in Oncology and the National Cancer Institute on a multicenter trial enrolling colorectal cancer patients and their relatives nationwide, including Puerto Rico. Labcorp will serve as the exclusive Invitae genetic testing provider, leveraging national scale and scientific expertise across academic and community oncology sites.
2. Focus on Cascade Testing and Multigene Panels
The trial aims to test proactive outreach by healthcare providers to increase germline testing among first-degree relatives, addressing that inherited variants account for roughly 10% of colorectal cancer cases while under one third of at-risk relatives currently undergo testing. It will also evaluate how multigene panel testing influences diagnostic and treatment decisions for newly diagnosed patients.
3. Strategic Impact for Labcorp
By supporting this high-impact clinical study, Labcorp extends its leadership in genetics-based oncology diagnostics, reinforcing its Invitae testing platform and strengthening relationships with research institutions. Successful outcomes could drive broader adoption of proactive genetic screening and multigene panels in cancer care, potentially boosting Labcorp’s future test volumes and market position.
